An Open-label Study of ALPN-303 in Subjects With Autoimmune Cytopenias
Status:
Not yet recruiting
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical study is to evaluate povetacicept (ALPN-303) in adults with
autoimmune cytopenias of immune thrombocytopenia, autoimmune hemolytic anemia, and cold
agglutinin disease to determine if povetacicept is safe and potentially beneficial in
treating these diseases. During the study treatment period participants will receive
povetacicept approximately every 4 weeks for 6 months, with the possibility of participating
in a 6-month study treatment extension period.